Ep192: Kate Haviland on Following the Science to Precision Immunology
8 de janeiro de 2026 · 1 h 26 min
Notas do episódio
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.